-Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021

Press/Media

Period13 May 2021

Media coverage

1

Media coverage

  • Title-Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021
    Media name/outletENP Newswire
    Country/TerritoryUnited Kingdom
    Date13/05/21
    PersonsMarina Kremyanskaya
View all 1
View less